COR
Cencora, Inc. NYSE Listed Apr 4, 1995$255.59
Mkt Cap $49.7B
52w Low $244.82
8.1% of range
52w High $377.54
50d MA $328.42
200d MA $328.15
P/E (TTM)
37.9x
EV/EBITDA
17.9x
P/B
33.7x
Debt/Equity
7.1x
ROE
85.2%
P/FCF
18.9x
RSI (14)
—
ATR (14)
—
Beta
0.72
50d MA
$328.42
200d MA
$328.15
Avg Volume
1.4M
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
1 West First Avenue · Conshohocken, PA 19428-1800 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 4.82 | 4.75 | -1.5% | 252.74 | +0.4% | +1.2% | — | — | — | — | — |
| Feb 4, 2026 | TNS | 4.05 | 4.08 | +0.7% | 329.97 | +1.9% | +6.7% | +8.9% | +10.1% | +9.1% | +10.8% | — |
| Nov 5, 2025 | TNS | 3.79 | 3.84 | +1.3% | 354.00 | -0.5% | +1.8% | +1.9% | +3.0% | +3.1% | +2.7% | — |
| Aug 6, 2025 | TNS | 3.85 | 4.00 | +3.9% | 283.78 | -0.9% | -1.9% | +0.5% | +2.4% | +1.9% | +2.6% | — |
| May 7, 2025 | TNS | 4.11 | 4.42 | +7.5% | 304.58 | -1.2% | -6.8% | -7.1% | -8.6% | -8.4% | -8.3% | — |
| Feb 5, 2025 | TNS | 3.50 | 3.73 | +6.6% | 253.28 | -1.1% | -2.8% | -2.1% | -2.7% | -2.6% | -3.8% | — |
| Nov 6, 2024 | TNS | 3.23 | 3.34 | +3.4% | 245.38 | +1.5% | +1.0% | +1.2% | +1.5% | +1.4% | +1.9% | — |
| Jul 31, 2024 | TNS | 3.22 | 3.34 | +3.7% | 237.88 | +0.9% | +2.8% | +4.1% | +1.4% | +0.8% | +1.4% | — |
| May 1, 2024 | TNS | 3.69 | 3.80 | +3.0% | 229.20 | -0.3% | -1.9% | -2.3% | -2.3% | -1.1% | -2.2% | — |
| Jan 31, 2024 | TNS | 2.89 | 3.28 | +13.5% | 232.68 | -0.0% | +1.8% | +1.0% | +0.7% | +1.0% | +2.1% | — |
| Nov 2, 2023 | TNS | 2.81 | 2.86 | +1.8% | 192.18 | +1.4% | +1.6% | +2.4% | +2.0% | +2.4% | +2.4% | — |
| Aug 2, 2023 | TNS | 2.82 | 2.92 | +3.5% | 191.43 | +0.6% | -0.0% | -3.2% | -2.5% | -3.2% | -3.0% | — |
| May 2, 2023 | BMO | 3.30 | 3.50 | +6.1% | 169.16 | +0.3% | -1.3% | -1.5% | -0.7% | -0.6% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | William Blair | Initiates | Mkt Perform | — | $310.16 | $310.50 | +0.1% | +0.6% | +0.4% | -0.7% | -2.0% | -2.1% |
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $320.89 | $323.45 | +0.8% | +1.3% | +0.5% | -0.0% | -0.6% | -0.3% |
| Feb 13 | Barclays | Maintains | Overweight → Overweight | — | $351.06 | $352.66 | +0.5% | +2.8% | +2.5% | +2.6% | +2.3% | +2.9% |
| Feb 10 | JP Morgan | Maintains | Overweight → Overweight | — | $363.27 | $362.47 | -0.2% | -0.9% | +0.7% | -3.4% | -0.7% | -0.9% |
| Feb 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $363.27 | $362.47 | -0.2% | -0.9% | +0.7% | -3.4% | -0.7% | -0.9% |
| Feb 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $329.97 | $336.08 | +1.9% | +6.7% | +8.9% | +10.1% | +9.1% | +10.8% |
| Jan 29 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $350.54 | $354.78 | +1.2% | +0.4% | +2.5% | +3.7% | +3.2% | -5.9% |
| Jan 22 | Jefferies | Upgrade | Hold → Buy | — | $351.75 | $356.14 | +1.2% | +0.2% | +0.5% | +1.1% | +1.2% | -0.3% |
| Jan 5 | BofA Securities | Maintains | Neutral → Neutral | — | $338.87 | $337.31 | -0.5% | +0.6% | +2.2% | +0.5% | -0.9% | -0.9% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $364.65 | $363.64 | -0.3% | +0.1% | -0.3% | +0.2% | -0.7% | +0.1% |
| Nov 11 | JP Morgan | Maintains | Overweight → Overweight | — | $364.65 | $363.64 | -0.3% | +0.1% | -0.3% | +0.2% | -0.7% | +0.1% |
| Nov 10 | TD Cowen | Maintains | Buy → Buy | — | $360.70 | $356.82 | -1.1% | +1.1% | +1.2% | +0.8% | +1.3% | +0.3% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $360.24 | $363.15 | +0.8% | +0.1% | +1.2% | +1.3% | +0.9% | +1.4% |
| Nov 6 | Mizuho | Maintains | Outperform → Outperform | — | $354.00 | $352.26 | -0.5% | +1.8% | +1.9% | +3.0% | +3.1% | +2.7% |
| Nov 6 | Baird | Maintains | Outperform → Outperform | — | $354.00 | $352.26 | -0.5% | +1.8% | +1.9% | +3.0% | +3.1% | +2.7% |
| Oct 30 | Mizuho | Maintains | Outperform → Outperform | — | $333.17 | $343.20 | +3.0% | +2.4% | +1.4% | +2.3% | +3.4% | +6.3% |
| Oct 27 | UBS | Maintains | Buy → Buy | — | $332.71 | $333.43 | +0.2% | +1.0% | +0.9% | +0.1% | +2.6% | +1.5% |
| Oct 16 | Mizuho | Maintains | Outperform → Outperform | — | $319.61 | $319.65 | +0.0% | -0.1% | +1.6% | +2.4% | +2.9% | +3.5% |
| Aug 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $289.15 | $291.29 | +0.7% | +0.7% | +2.0% | +1.3% | +0.4% | +1.9% |
| Jul 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $294.65 | $297.19 | +0.9% | +1.1% | -0.1% | -0.6% | -0.7% | -0.6% |
| Jun 30 | Jefferies | Maintains | Hold → Hold | — | $299.42 | $300.45 | +0.3% | +0.1% | -1.4% | -2.8% | -1.1% | +1.0% |
| Jun 3 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $292.07 | $295.52 | +1.2% | -0.2% | -1.0% | -1.3% | -1.1% | -2.8% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $304.58 | $301.00 | -1.2% | -6.8% | -7.1% | -8.6% | -8.4% | -8.3% |
| May 8 | Citigroup | Maintains | Buy → Buy | — | $304.58 | $301.00 | -1.2% | -6.8% | -7.1% | -8.6% | -8.4% | -8.3% |
| Apr 29 | UBS | Maintains | Buy → Buy | — | $287.75 | $288.43 | +0.2% | +0.8% | +1.7% | +0.9% | +1.5% | +1.5% |
| Apr 11 | BofA Securities | Maintains | Neutral → Neutral | — | $279.15 | $277.84 | -0.5% | +1.9% | +1.8% | +1.9% | +1.9% | +2.7% |
| Mar 14 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $256.01 | $255.59 | -0.2% | +0.8% | +1.9% | +3.2% | +3.8% | +4.6% |
| Feb 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $253.28 | $250.39 | -1.1% | -2.8% | -2.1% | -2.7% | -2.6% | -3.8% |
| Jan 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $255.10 | $257.05 | +0.8% | +0.3% | +1.3% | -0.3% | -0.3% | -1.4% |
| Jan 24 | JP Morgan | Maintains | Overweight → Overweight | — | $247.94 | $248.71 | +0.3% | +0.2% | +2.8% | +2.9% | +3.2% | +4.2% |
| Dec 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $232.12 | $232.48 | +0.2% | +0.1% | -1.0% | -1.9% | -2.2% | -2.5% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $245.38 | $249.04 | +1.5% | +1.0% | +1.2% | +1.5% | +1.4% | +1.9% |
| Nov 7 | Baird | Maintains | Outperform → Outperform | — | $245.38 | $249.04 | +1.5% | +1.0% | +1.2% | +1.5% | +1.4% | +1.9% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $245.38 | $249.04 | +1.5% | +1.0% | +1.2% | +1.5% | +1.4% | +1.9% |
| Nov 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $245.38 | $249.04 | +1.5% | +1.0% | +1.2% | +1.5% | +1.4% | +1.9% |
| Aug 21 | JP Morgan | Maintains | Overweight → Overweight | — | $238.41 | $238.76 | +0.1% | +0.4% | +0.9% | -0.3% | -1.7% | -2.1% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $237.88 | $240.10 | +0.9% | +2.8% | +4.1% | +1.4% | +0.8% | +1.4% |
| Aug 1 | Baird | Maintains | Outperform → Outperform | — | $237.88 | $240.10 | +0.9% | +2.8% | +4.1% | +1.4% | +0.8% | +1.4% |
| Jul 9 | Baird | Maintains | Outperform → Outperform | — | $223.69 | $225.51 | +0.8% | -0.6% | -0.6% | -0.8% | -0.5% | -0.7% |
| Jun 27 | Leerink Partners | Maintains | Outperform → Outperform | — | $237.28 | $229.00 | -3.5% | -3.9% | -5.0% | -5.8% | -6.2% | -6.2% |
| May 2 | Baird | Maintains | Outperform → Outperform | — | $229.20 | $228.49 | -0.3% | -1.9% | -2.3% | -2.3% | -1.1% | -2.2% |
| Apr 30 | Citigroup | Maintains | Buy → Buy | — | $239.93 | $239.78 | -0.1% | -0.4% | -4.5% | -6.3% | -6.7% | -6.6% |
| Feb 5 | Mizuho | Maintains | Neutral → Neutral | — | $234.99 | $237.33 | +1.0% | -0.3% | +0.0% | +1.1% | -2.0% | -1.8% |
| Aug 6 | TD Cowen | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $189.10 | $187.88 | -0.6% | +1.2% | +1.2% | -2.0% | -1.3% | -2.0% |
| Jul 10 | Mizuho | Maintains | Neutral → Neutral | — | $190.86 | $191.42 | +0.3% | +1.0% | +1.2% | -0.0% | +0.2% | +0.3% |
| Jun 6 | BofA Securities | Maintains | Buy → Buy | — | $174.69 | $175.03 | +0.2% | -0.2% | -0.6% | +1.0% | +2.0% | +2.7% |
| May 26 | JP Morgan | Maintains | Overweight → Overweight | — | $170.17 | $169.91 | -0.2% | -1.0% | -2.4% | -0.0% | +1.4% | +2.6% |
| May 26 | BofA Securities | Maintains | Buy → Buy | — | $170.17 | $169.91 | -0.2% | -1.0% | -2.4% | -0.0% | +1.4% | +2.6% |
| May 26 | Baird | Maintains | Outperform → Outperform | — | $170.17 | $169.91 | -0.2% | -1.0% | -2.4% | -0.0% | +1.4% | +2.6% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
COR's disclosure of forward-looking statements about EyeSouth Partners suggests potential strategic developments or operational updates that investors should monitor closely for impact on growth projections and earnings expectations.
Mar 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The 8-K contains only standard forward-looking statement disclaimers without material news, suggesting COR has no significant developments to disclose at this time.
Mar 17
8-K
Cencora, Inc. -- 8-K Filing
Cencora shareholders voted to approve executive compensation for fiscal 2025 and ratified Ernst & Young as the independent auditor for fiscal 2026.
Mar 6
8-K · 8.01
!! High
Cencora, Inc. -- 8-K 8.01: Material Event / Announcement
Cencora agreed to acquire MWI Veterinary Supply through a merger with Covetrus, valuing MWI at $3.5 billion enterprise value.
Feb 18
8-K · 1.01
! Medium
Cencora, Inc. -- 8-K 1.01: Financing / Debt Agreement
Cencora issued 2029 convertible notes under an existing indenture framework with U.S. Bank Trust Company, expanding its debt financing options and extending maturity obligations into 2029.
Feb 13
8-K · 7.01
! Medium
Cencora, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cencora disclosed material information via news release, which investors should review in the attached exhibit for updates on company developments or financial results.
Feb 11
8-K
Cencora, Inc. -- 8-K Filing
Cencora's 8-K filing reveals material corporate developments that could impact near-term stock performance, requiring investors to immediately review the specific disclosures to assess whether the news is positive or negative.
Feb 10
8-K · 7.01
! Medium
Cencora, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cencora disclosed non-material information to the SEC under Regulation FD, clarifying this disclosure isn't incorporated into other filings and carries limited liability implications for investors.
Feb 4
Data updated apr 25, 2026 2:41am
· Source: massive.com